79 related articles for article (PubMed ID: 20870699)
1. FDA places greater restrictions on access to rosiglitazone.
BMJ; 2010 Sep; 341():c5287. PubMed ID: 20870699
[No Abstract] [Full Text] [Related]
2. FDA committees say keep rosiglitazone available but increase warnings.
Tanne JH
BMJ; 2007 Aug; 335(7613):223. PubMed ID: 17673743
[No Abstract] [Full Text] [Related]
3. Rosiglitazone: what went wrong?
Cohen D
BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
[No Abstract] [Full Text] [Related]
4. Major US consumer group asks FDA to ban drug for diabetes.
Tanne JH
BMJ; 2008 Nov; 337():a2401. PubMed ID: 18987042
[No Abstract] [Full Text] [Related]
5. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
Freemantle N
BMJ; 2010 Sep; 341():c4812. PubMed ID: 20819888
[No Abstract] [Full Text] [Related]
6. Insiders criticise FDA's decision not to withdraw rosiglitazone.
Cohen D
BMJ; 2010 Sep; 341():c5333. PubMed ID: 20880925
[No Abstract] [Full Text] [Related]
7. FDA committee urges tight restrictions on rosiglitazone.
Roehr B
BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
[No Abstract] [Full Text] [Related]
8. Avandia panel member may be investigated for possible conflicts of interest.
Tanne JH
BMJ; 2010 Aug; 341():c4083. PubMed ID: 20682621
[No Abstract] [Full Text] [Related]
9. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
10. Anticipated US approval for rosiglitazone and pioglitazone.
Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298
[No Abstract] [Full Text] [Related]
11. FDA puts restrictions on use of controversial diabetes drug.
Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371
[No Abstract] [Full Text] [Related]
12. Licensing drugs for diabetes.
Lehman R; Yudkin JS; Krumholz H
BMJ; 2010 Sep; 341():c4805. PubMed ID: 20819887
[No Abstract] [Full Text] [Related]
13. European regulatory body recommends suspension of rosiglitazone.
Cohen D
BMJ; 2010 Sep; 341():c5291. PubMed ID: 20870700
[No Abstract] [Full Text] [Related]
14. Is the FDA on drugs?
Calabresi M; Park A
Time; 2010 Aug; 176(8):24-8. PubMed ID: 20821962
[No Abstract] [Full Text] [Related]
15. Rosiglitazone and the need for a new drug safety agency.
Garattini S; Bertele' V
BMJ; 2010 Oct; 341():c5506. PubMed ID: 20926483
[No Abstract] [Full Text] [Related]
16. Rosiglitazone: failure of oversight or demons imagined?
Susman J
J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
[No Abstract] [Full Text] [Related]
17. FDA puts rosiglitazone post-marketing trial on hold.
Cohen D
BMJ; 2010 Jul; 341():c4017. PubMed ID: 20660507
[No Abstract] [Full Text] [Related]
18. FDA panel advises easing restrictions on rosiglitazone.
Tucker ME
BMJ; 2013 Jun; 346():f3769. PubMed ID: 23752055
[No Abstract] [Full Text] [Related]
19. Responding to an FDA warning--geographic variation in the use of rosiglitazone.
Shah ND; Montori VM; Krumholz HM; Tu K; Alexander GC; Jackevicius CA
N Engl J Med; 2010 Nov; 363(22):2081-4. PubMed ID: 21083379
[No Abstract] [Full Text] [Related]
20. Serious liver injury. Leading reason for drug removals, restrictions.
Meadows M
FDA Consum; 2001; 35(3):8-9. PubMed ID: 11458559
[No Abstract] [Full Text] [Related]
[Next] [New Search]
